Hikma Pharmaceuticals PLC (LON:HIK)
United Kingdom · Delayed Price · Currency is GBP · Price in GBX 1,650.00
+6.00 (0.36%)
Nov 12, 2026, 4:35 PM GMT
Hikma Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Hikma Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of 2,004p. The average 1-year stock price forecast is 21.48% higher than the current stock price, while the lowest is 1,711p (+3.72%) and the highest is 2,664p (+61.44%).
Price Target: 2,004p (+21.48%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Hikma Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 8 | 8 | 8 | 8 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 12 | 12 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Berenberg Bank | Berenberg Bank | Buy Reiterates 2,100p → 2,050p | Buy | Reiterates | 2,100p → 2,050p | +24.24% | Nov 9, 2026 |
| Barclays | Barclays | Hold Maintains 1,700p | Hold | Maintains | 1,700p | +3.03% | Nov 6, 2026 |
| Jefferies | Jefferies | Buy Reiterates 2,025p | Buy | Reiterates | 2,025p | +22.73% | Nov 5, 2026 |
| Deutsche Bank | Deutsche Bank | Buy Reiterates 2,050p | Buy | Reiterates | 2,050p | +24.24% | Nov 3, 2026 |
| Citi | Citi | Buy Maintains 1,870p → 1,810p | Buy | Maintains | 1,870p → 1,810p | +9.70% | Oct 13, 2026 |
Financial Forecast
Revenue This Year
3.45B
from 3.35B
Increased by 3.02%
Revenue Next Year
3.56B
from 3.45B
Increased by 3.32%
EPS This Year
2.30
from 2.26
Increased by 1.80%
EPS Next Year
2.47
from 2.30
Increased by 7.22%
EPS and Forward PE are based on non-GAAP adjusted numbers.